In addition to PD-1, SCCHN may also evade antitumor immunity through multiple mechanisms, including programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)9. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.